Medpace Holdings Beheer
Beheer criteriumcontroles 4/4
Medpace Holdings' CEO is August Troendle, appointed in Jul 1992, has a tenure of 32.33 years. total yearly compensation is $1.65M, comprised of 49.5% salary and 50.5% bonuses, including company stock and options. directly owns 17.37% of the company’s shares, worth $1.72B. The average tenure of the management team and the board of directors is 5.8 years and 6.3 years respectively.
Belangrijke informatie
August Troendle
Algemeen directeur
US$1.6m
Totale compensatie
| Percentage CEO-salaris | 49.5% |
| Dienstverband CEO | 32.3yrs |
| Eigendom CEO | 17.4% |
| Management gemiddelde ambtstermijn | 5.8yrs |
| Gemiddelde ambtstermijn bestuur | 6.3yrs |
Recente managementupdates
Recent updates
Medpace: Buy The Short-Term Pain For Long-Term Gains
Oct 26Why Medpace Holdings Is A 'Better Mousetrap'
Oct 16Medpace Holdings, Inc.'s (NASDAQ:MEDP) Earnings Haven't Escaped The Attention Of Investors
Sep 19
Should You Be Adding Medpace Holdings (NASDAQ:MEDP) To Your Watchlist Today?
Sep 02Medpace: Continued Business Growth With Asymmetrical Payoff Opportunity
Aug 20Why Medpace Holdings' (NASDAQ:MEDP) Earnings Are Better Than They Seem
Jul 31Medpace Holdings, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Jul 25What You Can Learn From Medpace Holdings, Inc.'s (NASDAQ:MEDP) P/E
Jun 18Medpace: Clear Winner If China Blockade Succeeds
Jun 04A Look At The Fair Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)
May 22Does Medpace Holdings (NASDAQ:MEDP) Deserve A Spot On Your Watchlist?
Apr 12Medpace: Exceptional Performance, Almost Fully Priced In
Mar 11Medpace Holdings, Inc.'s (NASDAQ:MEDP) 32% Jump Shows Its Popularity With Investors
Feb 18Should You Think About Buying Medpace Holdings, Inc. (NASDAQ:MEDP) Now?
Feb 09A Look At The Intrinsic Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)
Jan 25Should You Be Adding Medpace Holdings (NASDAQ:MEDP) To Your Watchlist Today?
Jan 10Shareholders Should Be Pleased With Medpace Holdings, Inc.'s (NASDAQ:MEDP) Price
Dec 26Should You Investigate Medpace Holdings, Inc. (NASDAQ:MEDP) At US$275?
Nov 08Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Could Be 29% Below Their Intrinsic Value Estimate
Oct 23If EPS Growth Is Important To You, Medpace Holdings (NASDAQ:MEDP) Presents An Opportunity
Oct 10Does Medpace Holdings (NASDAQ:MEDP) Have A Healthy Balance Sheet?
Aug 27Should You Think About Buying Medpace Holdings, Inc. (NASDAQ:MEDP) Now?
Jul 31A Look At The Fair Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)
Jul 18Here's Why We Think Medpace Holdings (NASDAQ:MEDP) Might Deserve Your Attention Today
Jul 04Is Medpace Holdings (NASDAQ:MEDP) A Risky Investment?
May 25Is Now The Time To Look At Buying Medpace Holdings, Inc. (NASDAQ:MEDP)?
Apr 27An Intrinsic Calculation For Medpace Holdings, Inc. (NASDAQ:MEDP) Suggests It's 28% Undervalued
Apr 12We Ran A Stock Scan For Earnings Growth And Medpace Holdings (NASDAQ:MEDP) Passed With Ease
Mar 27Does Medpace Holdings (NASDAQ:MEDP) Have A Healthy Balance Sheet?
Feb 14What Is Medpace Holdings, Inc.'s (NASDAQ:MEDP) Share Price Doing?
Jan 16Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Could Be 41% Below Their Intrinsic Value Estimate
Jan 03Here's Why We Think Medpace Holdings (NASDAQ:MEDP) Might Deserve Your Attention Today
Dec 20Medpace Holdings (NASDAQ:MEDP) Has A Rock Solid Balance Sheet
Nov 16Growth Investors: Industry Analysts Just Upgraded Their Medpace Holdings, Inc. (NASDAQ:MEDP) Revenue Forecasts By 13%
Nov 03Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$366m |
| Jun 30 2024 | n/a | n/a | US$340m |
| Mar 31 2024 | n/a | n/a | US$312m |
| Dec 31 2023 | US$2m | US$814k | US$283m |
| Sep 30 2023 | n/a | n/a | US$273m |
| Jun 30 2023 | n/a | n/a | US$268m |
| Mar 31 2023 | n/a | n/a | US$257m |
| Dec 31 2022 | US$2m | US$770k | US$245m |
| Sep 30 2022 | n/a | n/a | US$227m |
| Jun 30 2022 | n/a | n/a | US$209m |
| Mar 31 2022 | n/a | n/a | US$199m |
| Dec 31 2021 | US$6m | US$697k | US$181m |
| Sep 30 2021 | n/a | n/a | US$182m |
| Jun 30 2021 | n/a | n/a | US$175m |
| Mar 31 2021 | n/a | n/a | US$159m |
| Dec 31 2020 | US$4m | US$608k | US$145m |
| Sep 30 2020 | n/a | n/a | US$124m |
| Jun 30 2020 | n/a | n/a | US$107m |
| Mar 31 2020 | n/a | n/a | US$110m |
| Dec 31 2019 | US$8m | US$504k | US$100m |
| Sep 30 2019 | n/a | n/a | US$93m |
| Jun 30 2019 | n/a | n/a | US$88m |
| Mar 31 2019 | n/a | n/a | US$78m |
| Dec 31 2018 | US$528k | US$420k | US$73m |
| Sep 30 2018 | n/a | n/a | US$61m |
| Jun 30 2018 | n/a | n/a | US$52m |
| Mar 31 2018 | n/a | n/a | US$45m |
| Dec 31 2017 | US$598k | US$419k | US$39m |
Compensatie versus markt: August's total compensation ($USD1.65M) is below average for companies of similar size in the US market ($USD12.87M).
Compensatie versus inkomsten: August's compensation has been consistent with company performance over the past year.
CEO
August Troendle (68 yo)
32.3yrs
Tenure
US$1,646,031
Compensatie
Dr. August James Troendle, M.D. serves as Chairman of CinRx Pharma, LLC. He has been the Chairman, Chief Executive Officer at Medpace Holdings, Inc. since July 1992 and served as its President since July 1...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & CEO | 32.3yrs | US$1.65m | 17.37% $ 1.7b | |
| President | 3.3yrs | US$945.08k | 0.069% $ 6.9m | |
| CFO & Treasurer | 5.8yrs | US$690.48k | 0.019% $ 1.9m | |
| Executive Vice President of Operations | 7.8yrs | US$1.12m | 0.19% $ 18.4m | |
| Chief Compliance Officer | 12.4yrs | US$914.64k | 0.043% $ 4.3m | |
| Chief Information Officer | 3.8yrs | geen gegevens | geen gegevens | |
| Associate Director of Investors Relations | no data | geen gegevens | geen gegevens | |
| Vice President of Business Development & Marketing | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Commercial Operations & Clinical Pharmacology Unit | no data | geen gegevens | geen gegevens | |
| Chief Medical Officer of Medical Department | 1.8yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Clinical Monitoring | no data | geen gegevens | geen gegevens |
5.8yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren management: MEDP's management team is seasoned and experienced (5.8 years average tenure).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & CEO | 32.3yrs | US$1.65m | 17.37% $ 1.7b | |
| Lead Independent Director | 6.3yrs | US$264.98k | 0.0065% $ 639.2k | |
| Independent Director | 6.3yrs | US$217.48k | 0.017% $ 1.7m | |
| Independent Director | 8.3yrs | US$227.35k | 0.0019% $ 189.3k | |
| Independent Director | 8.3yrs | US$234.97k | 0.070% $ 7.0m | |
| Independent Director | 1.8yrs | US$258.37k | 0% $ 0 | |
| Director | less than a year | geen gegevens | geen gegevens |
6.3yrs
Gemiddelde duur
66yo
Gemiddelde leeftijd
Ervaren bestuur: MEDP's board of directors are considered experienced (6.3 years average tenure).